Lazard Asset Management
AMRX icon

Lazard Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Lazard Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$750K Sell
43,316
-11,170
-21% -$153K ﹤0.01% 1304
2026
Q1 		$677K Buy
54,486
+86
+0.2% +$1.16K ﹤0.01% 1289
2025
Q4 		$685K Buy
54,400
+5
+0% +$57 ﹤0.01% 1264
2025
Q3 		$544K Sell
54,395
-2,038
-4% -$18.3K ﹤0.01% 1331
2025
Q2 		$455K Buy
56,433
+5,643
+11% +$42.5K ﹤0.01% 1511
2025
Q1 		$424K Buy
50,790
+8,727
+21% +$72.8K ﹤0.01% 1447
2024
Q4 		$332K Buy
42,063
+11,764
+39% +$98.7K ﹤0.01% 1478
2024
Q3 		$251K Sell
30,299
-47,829
-61% -$374K ﹤0.01% 1554
2024
Q2 		$495K Buy
78,128
+77,167
+8,030% +$490K ﹤0.01% 1203
2024
Q1 		$5K Buy
961
+2
+0.2% +$11 ﹤0.01% 1897
2023
Q4 		$5K Buy
+959
New +$4.27K ﹤0.01% 2120
2023
Q2 		– Sell
-4,079
Closed -$5K – 2285
2023
Q1 		$5K Sell
4,079
-12,834
-76% -$25.6K ﹤0.01% 2160
2022
Q4 		$33K Hold
16,913
– – ﹤0.01% 1977
2022
Q3 		$34K Buy
16,913
+4,079
+32% +$11.4K ﹤0.01% 1938
2022
Q2 		$40K Hold
12,834
– – ﹤0.01% 1905
2022
Q1 		$53K Hold
12,834
– – ﹤0.01% 1707
2021
Q4 		$61K Buy
12,834
+2,494
+24% +$12.4K ﹤0.01% 1644
2021
Q3 		$55K Buy
+10,340
New +$52.1K ﹤0.01% 1636
2021
Q2 		– Sell
-4,206
Closed -$28K – 1949
2021
Q1 		$28K Sell
4,206
-3,084
-42% -$17.1K ﹤0.01% 1665
2020
Q4 		$33K Buy
+7,290
New +$32.3K ﹤0.01% 1525
2020
Q3 		– Sell
-11,839
Closed -$56K – 1601
2020
Q2 		$56K Buy
+11,839
New +$48.8K ﹤0.01% 1199

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Lazard Asset Management's AMRX Position: Q2 2026 in Review

Lazard Asset Management reduced its Amneal Pharmaceuticals (AMRX) stake by 21% in Q2 2026, selling an estimated $153K and leaving 43,316 shares worth $750K. The position accounts for ﹤0.01% of the portfolio, ranked #1304.

Lazard Asset Management first reported a position in AMRX in Q2 2020 and has held it in 21 quarters since. 310 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Lazard Asset Management held 43,316 shares of Amneal Pharmaceuticals worth $750K as of Q2 2026.
  • Lazard Asset Management sold 11,170 Amneal Pharmaceuticals shares in Q2 2026, an estimated $153K.
  • Amneal Pharmaceuticals made up ﹤0.01% of Lazard Asset Management's portfolio in Q2 2026, its #1304 holding.
  • Lazard Asset Management first reported a position in Amneal Pharmaceuticals in Q2 2020 and has held it in 21 quarters since.
  • 310 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.